What are the recommended non‑pharmacologic and pharmacologic strategies to treat restlessness and insomnia in a patient with vascular dementia?

Management of Restlessness and Insomnia in Vascular Dementia

Begin with non-pharmacological interventions as first-line treatment, and if pharmacotherapy becomes necessary, use low-dose trazodone (50 mg) for sleep or quetiapine for combined restlessness and sleep problems, while strictly avoiding benzodiazepines.

Non-Pharmacological Strategies (First-Line Treatment)

Behavioral interventions should be exhausted before any medication is considered 1, 2. These approaches are person-centered, have no harmful effects, and provide sustained long-term benefits:

Sleep Hygiene and Stimulus Control

Implement these specific measures 1:

• Maintain consistent sleep-wake times: Same bedtime and wake time daily, regardless of sleep obtained
• Limit time in bed to actual sleep time (sleep restriction therapy)
• Eliminate daytime napping or restrict to 30 minutes before 2 PM
• Use bedroom only for sleep: No TV, work, or stimulating activities
• Leave bedroom if unable to sleep within 20-30 minutes; return only when sleepy
• Avoid sleep-fragmenting substances: No caffeine, nicotine, or alcohol in evening
• Optimize bedroom environment: Cool, dark, quiet, comfortable
• Establish 30-minute relaxation ritual before bedtime

Environmental and Behavioral Modifications for Restlessness

Address the underlying triggers 2:

• Provide predictable daily routine: Fixed times for meals, exercise, activities, bedtime
• Ensure adequate daytime stimulation: Physical activities, social engagement, meaningful tasks
• Use lighting strategically: Bright light exposure during day, reduced stimulation at night to minimize confusion
• Simplify the environment: Remove clutter, secure loose rugs, eliminate glare from windows/mirrors
• Apply the "three R's": Repeat instructions, Reassure the patient, Redirect to calming activities

Physical and Social Activities

Physical exercise and social engagement may improve sleep parameters 1. Consider walking, Tai Chi, or structured activity programs, but avoid heavy exercise within 2 hours of bedtime.

Pharmacological Strategies (When Non-Pharmacological Approaches Fail)

For Insomnia Specifically

Trazodone 50 mg at bedtime is the most evidence-supported option for sleep in dementia patients 3. Low-quality evidence shows it:

• Increases total nocturnal sleep time by approximately 42 minutes
• Improves sleep efficiency by 8.5%
• Has minimal serious adverse effects in short-term use (2 weeks studied)
• Does not affect cognition or activities of daily living

Avoid these medications for sleep 1:

• Benzodiazepines: The 2005 NIH State-of-Science Conference warned that risks outweigh benefits in older adults; no systematic evidence for effectiveness 1
• Antihistamines, antipsychotics (for sleep alone), anticonvulsants: Risks exceed benefits 1
• Melatonin (up to 10 mg): No evidence of benefit in moderate-to-severe dementia 3
• Ramelteon: No effect on sleep outcomes in mild-to-moderate dementia 3

For Combined Restlessness and Sleep Problems

When agitation/restlessness accompanies insomnia, quetiapine demonstrated the lowest adverse event profile in older adults with severe agitation 4. A 2025 systematic review found quetiapine had significantly fewer adverse events compared to haloperidol (OR 0.27 [95% CI: 0.08,0.97]).

Critical safety warnings for agitation management 4:

• Avoid midazolam and benzodiazepines: 53% adverse event rate with midazolam; 5.25-fold increased risk versus haloperidol
• Start all medications at lowest available dose 1
• Monitor for: Respiratory depression, falls, delirium exacerbation, hypotension, cognitive worsening

Medication Selection Algorithm

1. If insomnia is the primary problem: Trazodone 50 mg at bedtime
2. If restlessness/agitation with insomnia: Quetiapine (start low dose, typically 12.5-25 mg)
3. If depression coexists: Consider citalopram or sertraline (minimal anticholinergic effects) 2
4. Never use as first-line: Benzodiazepines, antihistamines, or high-dose antipsychotics

Critical Pitfalls to Avoid

• Do not use benzodiazepines in older adults with dementia: Observational studies link hypnotics to increased dementia progression, fractures, and major injury 5. The 2025 geriatric emergency guidelines specifically warn against benzodiazepines, particularly midazolam 4.

• Older adults have increased sensitivity to sedatives: Reduced drug clearance and increased peak drug effects mean standard doses cause disproportionate harm 1

• Combination therapy may be beneficial: One RCT in older adults showed combining behavioral therapy with medication was more efficacious than either alone, though behavioral benefits were better sustained long-term 1

• Reassess regularly: Pharmacotherapy should be time-limited; continue non-pharmacological approaches throughout treatment 1, 6

The evidence strongly favors exhausting behavioral interventions first, as they provide sustained benefits without the significant risks associated with pharmacotherapy in this vulnerable population 1, 2, 1.